Keros Stock Crash: Drug Cibotercept Faces Safety Issues
Keros Stock– Keros Therapeutics (KROS) is encountering significant challenges in its clinical trial for cibotercept, a drug being tested in patients with pulmonary arterial hypertension (PAH), a condition marked by high blood pressure in the lungs. The company recently reported issues with higher doses of cibotercept, which caused an unexpected safety concern — excess fluid buildup around the heart, known as pericardial effusion. This safety concern has raised alarms among investors and analysts, leading to a steep decline in Keros stock price.
Setback in Clinical Trials: Excess Fluid and Pericardial Effusion
Cibotercept, which is designed to target a group of proteins known as activin, has shown promise in earlier preclinical studies. However, the latest trial results revealed a significant safety issue when patients were given the higher doses of the drug. Specifically, the 3 milligram and 4.5 milligram per kilogram doses led to the development of pericardial effusion, a condition where excess fluid accumulates in the sac around the heart. As a result, Keros Therapeutics has voluntarily suspended these higher doses, opting to continue testing the lower 1.5 milligram per kilogram dose.
Despite the setback, the company remains focused on its ongoing trials at the lower dose, which has not shown the same adverse effects. However, the news has already had a significant impact on the stock price, reflecting growing investor concerns about the future of cibotercept.
Keros Stock Plummets After Safety Concerns
The news of the safety concerns surrounding cibotercept triggered a sharp drop in Keros Therapeutics’ stock. Shares of Keros plunged by 73.2% on the day of the announcement, closing at $18.43. This dramatic decline marks a significant setback for the company, which had previously been riding on high expectations for cibotercept as its lead program and major growth driver.
According to analysts, the stock’s poor performance is indicative of the severe investor reaction to the news. “We view this as a major setback and are unsurprised by the significant pressure on KROS shares,” said Thomas Smith, an analyst at Leerink Partners. The drop in stock price also saw Keros’ shares undercut their 50-day and 200-day moving averages, further indicating the challenges the company now faces.
Analysts React to the Setback
The news of pericardial effusion has caught many analysts off guard, particularly given the encouraging results from earlier studies. William Blair analyst Matt Phipps expressed his shock at the development, noting that preclinical studies had shown higher doses of cibotercept were safe after six months of testing, and there were no signs of pericardial effusion in healthy volunteers during three-month studies.
However, the recent safety findings have led Phipps to downgrade Keros Therapeutics’ stock. He lowered his rating from “Outperform” to “Market Perform,” reflecting the uncertainty surrounding cibotercept’s future development. “We believe the clinical setback will make it difficult to regain investor interest in cibotercept, which was the company’s lead program and main value driver,” Phipps wrote in his report.
Keros Competes with Merck’s PAH Drug Winrevair
As Keros faces these challenges, it is also competing against other companies, such as Merck, which has already received FDA approval for its own PAH drug, Winrevair. Winrevair and cibotercept both target activin, a protein group involved in inflammation, making them direct competitors in the PAH space.
Merck’s Winrevair, which was approved in March 2024, has already gained a strong foothold in the market. Phipps points out that it will take more data to convince physicians, patients, and investors that cibotercept offers unique benefits compared to Winrevair. Until then, the competition from established players like Merck could pose a significant challenge to Keros’ prospects in the PAH market.
Optimism from Wedbush Analyst Amidst Uncertainty
Despite the concerns surrounding the safety of cibotercept, some analysts are still holding out hope for the drug’s potential. Wedbush analyst Yun Zhong remains optimistic about Keros’ prospects, maintaining an “Outperform” rating on the stock, although he has significantly reduced his price target for Keros shares, from $84 to $47.
Zhong acknowledged the uncertainties caused by the unexpected safety findings but still believes that the program remains viable. He pointed out that data from the ongoing trials at the lower 1.5 mg/kg dose in the second quarter of 2025 could provide critical insights that might support the continued development of cibotercept. “Although we recognize the significant uncertainties created by the unexpected safety findings, we believe the program is still viable,” Zhong said in his report.
Looking Ahead: Will Keros Recover?
The future of Keros Therapeutics and its drug cibotercept remains uncertain. The company’s immediate focus will likely be on continuing the clinical trials at the lower 1.5 milligram per kilogram dose, which has not shown the same safety issues as the higher doses. However, it is clear that the company faces a significant challenge in regaining investor confidence and continuing to develop cibotercept as a viable treatment for PAH.
For Keros, the road ahead will require not only overcoming safety concerns but also demonstrating that cibotercept can offer something unique compared to established treatments like Winrevair. Whether the company can recover from this setback and find success in future trials remains to be seen. However, for investors and stakeholders, this is undoubtedly a critical juncture in Keros Therapeutics’ journey.
Challenges and Uncertainty for Keros Therapeutics
Keros Therapeutics is navigating turbulent waters after its drug cibotercept encountered unexpected safety concerns in clinical trials. The company’s decision to suspend higher doses of the drug in favor of testing a lower dose is a step toward managing the issue, but the impact on its stock price and investor confidence cannot be understated. With strong competition from Merck’s FDA-approved drug, Winrevair, and an uncertain future for cibotercept, Keros faces an uphill battle in the pulmonary arterial hypertension market. Only time will tell if the company can overcome this challenge and regain its footing in the market.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Cryptocurrencies and stocks, particularly in micro-cap companies, are subject to significant volatility and risk. Please conduct thorough research before making any investment decisions.
Leave a comment